The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The serendipitous cloning in 1990 of the first of such proteins, the CB 1 receptor, came from the screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligand”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
Items 501–600 of 1,001
Köck, P., Badek, A., Meyer, M., Klaassen, A.-L., Walter, M., & Kindler, J. (2024) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-024-00846-5 · Cited by 29
Therapeutic Use of Palmitoylethanolamide as an Anti-Inflammatory and Immunomodulator
de Sá, M. C. I., & Castor, M. G. M. E. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3040058 · Cited by 29
Getting to the core of addiction: Hooking CB2 receptor into drug abuse?
Morales, M., & Bonci, A. (2012) · Nature Medicine · doi:10.1038/nm.2722 · Cited by 29
Smoking cessation pharmacotherapy
Frishman, W. H. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709335754 · Cited by 29
“The selective cannabinoid-1 receptor blockers (CB1) are thought to modulate systems in the brain that are altered by cigarette smoke [DiMarzo et al. 2004].”
BackgroundZhu, H., & Han, M. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-041814-095928 · Cited by 29
Chen, J., Varga, A., Selvarajah, S., Jenes, Á., Dienes, B., Valente, J. D. S., Kulik, Á., Veress, G., Brain, S. D., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep33307 · Cited by 29
Tutino, V., Caruso, M. G., Nunzio, V. D., Lorusso, D., Veronese, N., Gigante, I., Notarnicola, M., & Giannelli, G. (2019) · Cancers · doi:10.3390/cancers11050708 · Cited by 29
“ECS has been demonstrated to have a role in the regulation of signaling pathways involved in cancer pathogenesis [2,3].”
BackgroundBruno, A., Lembo, F., Novellino, E., Stornaiuolo, M., & Marinelli, L. (2014) · Scientific Reports · doi:10.1038/srep03757 · Cited by 29
Müller, T. D., Brönner, G., Wandolski, M., Carrie, J., Nguyen, T. T. H., Greene, B., Scherag, A., Grallert, H., Vogel, C. I. G., Scherag, S., et al. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-2 · Cited by 29
“A characteristic feature of endocannabinoids is that they are synthesized by cells on demand and undergo a rapid degradation through specific hydrolases and lipases [1,8,9].”
BackgroundEndocannabinoids and Their Role in Fatty Liver Disease
Mallat, A., & Lotersztajn, S. (2010) · Digestive Diseases · doi:10.1159/000282100 · Cited by 29
Buggy, Y., Cornelius, V. R., Wilton, L., & Shakir, S. (2011) · Drug Safety · doi:10.2165/11588510-000000000-00000 · Cited by 29
de Lago, E., Gustafsson, S. B., Fernández‐Ruíz, J., Nilsson, J. A., Jacobsson, S. O. P., & Fowler, C. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04104.x · Cited by 29
“…investigation at present, not the least in view of the therapeutic possibilities afforded by its modulation, including the treatment of multiple sclerosis, obesity and glioma (for reviews, see, for example, Di Marzo et al. 2004; Velasco et al. 2004; Lambert and Fowler 2005; Pryce and Baker 2005).”
BackgroundCannabinoid-1 receptor antagonists in type-2 diabetes
Scheen, A. J. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.08.005 · Cited by 29
Casteels, C., Koole, M. J. B., Celen, S., Bormans, G. M., & Laere, K. V. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2163-3 · Cited by 28
“The brain CB1 receptor plays an important role in homeostatic mechanisms [2] and is involved in pathophysiological conditions such as epilepsy, addiction, stroke, eating disorders, schizophrenia and movement disorders (for reviews see [3, 4]).”
BackgroundFeng, W., Qin, C., Abdelrazig, S., Bai, Z., Raji, M., Darwish, R., Chu, Y., Ji, L., Gray, D. A., Stocks, M. J., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121947 · Cited by 28
Dai, Z., Zhang, Y., Meng, Y., Li, S., Suonan, Z., Sun, Y., Ji, J., Shen, Q., Zheng, H., & Xue, Y. (2023) · Food Chemistry · doi:10.1016/j.foodchem.2023.135980 · Cited by 28
Naderi, N., Ahmad-Molaei, L., Mazar-Atabaki, A., Ronaghi, A., Shirazi-zand, Z., Langroudi, S. M. M., & Eslahkar, S. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0607-y · Cited by 28
Dotsey, E. Y., Ushach, I., Pone, E. J., Nakajima, R., Jasinskas, A., Argueta, D. A., Dillon, A., DiPatrizio, N. V., Davies, H., Zlotnik, A., et al. (2017) · Scientific Reports · doi:10.1038/srep42584 · Cited by 28
Highly Selective, Amine‐Derived Cannabinoid Receptor 2 Probes
Westphal, M. V., Sarott, R. C., Zirwes, E. A., Osterwald, A., Guba, W., Ullmer, C., Grether, U., & Carreira, E. M. (2020) · Chemistry - A European Journal · doi:10.1002/chem.201904584 · Cited by 28
Synergistic effects of HIV and marijuana use on functional brain network organization
Hall, S. A., Lalee, Z., Bell, R. P., Towe, S. L., & Meade, C. S. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110040 · Cited by 28
Chiba, T., Ueno, S., Obara, Y., & Nakahata, N. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01250.x · Cited by 28
“Cannabinoids, which include the bioactive constituents of the marijuana plant Cannabis sativa and its synthetic or endogenous counterparts, modulate a range of central nervous system (CNS) functions and affect peripheral sites such as immune function and the cardiovascular system.([1,2]) Several endogenous cannabinoid…”
BackgroundObesity and the Endocannabinoid System: Circulating Endocannabinoids and Obesity
Matias, I., Gatta‐Cherifi, B., & Cota, D. (2012) · Current Obesity Reports · doi:10.1007/s13679-012-0027-6 · Cited by 28
“The ECS comprises two distinct membrane receptors, the cannabinoid receptor type 1 (CB1) and type 2 (CB2), specific ligands named endocannabinoids and enzymes responsible of ligand biosynthesis and degradation [7, 8].”
BackgroundSzczesniak, A.-M., Maor, Y., Robertson, H. A., Hung, O. R., & Kelly, M. E. M. (2011) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0041 · Cited by 28
Peripheral Metabolic Effects of Endocannabinoids and Cannabinoid Receptor Blockade
Engeli, S. (2008) · Obesity Facts · doi:10.1159/000114255 · Cited by 28
Correia‐Sá, I., Carvalho, C., Serrão, P., Loureiro, A. I., Fernandes‐Lopes, C., Marques, M., & Vieira‐Coelho, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68058-3 · Cited by 27
Naturally Occurring Cannabinoids and their Role in Modulation of Cardiovascular Health
Azari, E. K., Kerrigan, A., & O’Connor, A. (2020) · Journal of Dietary Supplements · doi:10.1080/19390211.2020.1790708 · Cited by 27
“…and 2-arachidonoylglycerol (2-AG), (2) their biosynthetic and metabolic enzymes including fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), and (3) a widespread network of cannabinoid receptors, such as cannabinoid receptor type 1 and type 2 (CB1 and CB2) (Di Marzo et al. 2004).”
BackgroundSchiavi, S., Manduca, A., Carbone, E., Buzzelli, V., Rava, A., Feo, A., Ascone, F., Morena, M., Campolongo, P., Hill, M. N., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01454-7 · Cited by 27
Medial prefrontal cortex endocannabinoid system modulates baroreflex activity through CB1receptors
Ferreira‐Junior, N. C., Fedoce, A. G., Alves, F. H. F., Corrêa, F. M. D. A., & Resstel, L. B. M. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00330.2011 · Cited by 27
“In the central nervous system (CNS), the endocannabinoid anandamide is synthesized on demand in postsynaptic neurons, after calcium influx increase (13, 42).”
Qiao, C.-J., Ali, H. I., Ahn, K. H., Kolluru, S., Kendall, D. A., & Lu, D. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.044 · Cited by 27
“Traditionally, drug discovery, targeting the CB1 receptor, has focused on agonists and inverse agonists/antagonists that bind to the orthosteric ligand binding site where the endogenous ligands of cannabinoid receptors bind [7].”
BackgroundAneetha, H., O’Dell, D. K., Tan, B., Walker, J. M., & Hurley, T. D. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.087 · Cited by 27
McCulloch, M., Zhou, X., Xu, Y., Brunell, S. C., & SPEAR, L. P. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.01.020 · Cited by 27
Gastón, R. M. P., Pasqualini, M. E., Das, U. N., & Eynard, A. R. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.01.009 · Cited by 27
Boulebd, H., Pereira, D. M., Khodja, I. A., Hòa, N. T., Mechler, Á., & Vo, Q. V. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.118277 · Cited by 26
Role of Gut Microbiota in Cannabinoid-Mediated Suppression of Inflammation
Varsha, K. K., Nagarkatti, M., & Nagarkatti, P. S. (2022) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2022.10550 · Cited by 26
“The CB1 and CB2 receptors are expressed primarily in the brain and immune cells respectively and mediate nearly all the effects of both endogenous and exogenous cannabinoids (6, 7).”
Hydroxytyrosol Inhibits Cannabinoid CB1 Receptor Gene Expression in 3T3‐L1 Preadipocyte Cell Line
Tutino, V., Orlando, A., Russo, F., & Notarnicola, M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25094 · Cited by 26
“The ECS consists of endogenous cannabinoids (endocannabinoids), cannabinoid receptors (CB1 and CB2), as well as enzymes that synthesize and degrade the endocannabinoids (Di Marzo et al., 2004).”
BackgroundWhat are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 26
“Rimonabant, a selective blocker of cannabinoid CB1 receptors [81], was investigated in the Rimonabant in Obesity (RIO) trial [82] to assess the drug’s effect on development of diabetes in obese prediabetic individuals [83].”
BackgroundGérard, N., Ceccarini, J., Bormans, G. M., Vanbilloen, B., Casteels, C., Goffin, K. E., Bosier, B., Lambert, D. M., & Laere, K. V. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9340-2 · Cited by 26
Komaki, H., Saadat, F., Shahidi, ., Sarihi, A., Hasanein, P., & Komaki, A. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.04.009 · Cited by 26
“Ca2+ influx is a necessary step, both in neurotransmitter release and in the synthesis of eCBs (Di Marzo et al., 2004).”
Freundt-Revilla, J., Heinrich, F., Zoerner, A. A., Gesell, F. K., Beyerbach, M., Shamir, M. H., Oevermann, A., Baumgärtner, W., & Tipold, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0187197 · Cited by 26
“The most bioactive ECs and the best studied ones are Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) [4, 6, 7].”
BackgroundThe neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study
Borgan, F., O’Daly, O., Veronese, M., Marques, T. R., Laurikainen, H., Hietala, J. A., & Howes, O. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0619-6 · Cited by 26
Liao, Y., Bin, J., Asakura, M., Xuan, W., Chen, B., Huang, Q., Xu, D., Ledent, C. A., Takashima, S., & Kitakaze, M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr246 · Cited by 26
“Accumulated evidence shows that endocannabinoids seem to be produced ‘on demand’.(40) Our findings in this study suggest that endocannabinoids fulfill a protective role in AHF.”
3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors
Urbach, A., Muccioli, G. G., Stern, E., Lambert, D. M., & Marchand‐Brynaert, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.081 · Cited by 26
Rojek, S. D., Kłys, M., Maciów‐Głąb, M., & Kula, K. (2017) · Legal Medicine · doi:10.1016/j.legalmed.2017.06.004 · Cited by 25
Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats
Zubrzycki, M., Janecka, A. E., Liebold, A., Ziegler, M., & Zubrzycka, M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13970 · Cited by 25
“…the two major cannabinoid receptors, CB1 and CB2 receptors, their endogenous ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), which regulate their biosynthesis and degradation (Di Marzo et al., 2004).”
BackgroundMella, J., Lagos, C. F., Recabarren‐Gajardo, G., Espinosa‐Bustos, C., Romero‐Parra, J., Pessoa-Mahana, H. A., Iturriaga‐Vásquez, P., & Pessoa-Mahana, C. D. (2013) · Molecules · doi:10.3390/molecules18043972 · Cited by 25
“Its physiological effects are mediated through the so-called cannabinoid receptors, which are attractive targets for current drug development [6,7].”
BackgroundGastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids
Abdel‐Salam, O. M. E. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.04.021 · Cited by 25
Role of the Endocannabinoid System and Medical Cannabis
Jarvis, S., Rassmussen, S., & Winters, B. A. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2017.05.014 · Cited by 25
“Endocannabinoids, their receptors, and the associated mediating enzymes for synthesis and degradation comprise the endocannabinoid system (ECS).(8) In the US there are 3 categories of cannabinoid medicines: single molecule drugs; cannabis-based liquid extracts; and phytocannabinoid botanicals.”
BackgroundChast, F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00001-9 · Cited by 25
The Pharmacology of the Cannabinoid System—A Question of Efficacy and Selectivity
Fowler, C. J. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0001-6 · Cited by 25
“been, or are being, elucidated (for reviews, see [3, 4]).”
BackgroundJayanthi, S., Buie, S., Moore, S., Herning, R. I., BETTER, W. E., Wilson, N. M., Contoreggi, C. S., & Cadet, J. L. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.50 · Cited by 25
A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease
Cury, R. D. M., da Silva, T., Cezar‐dos‐Santos, F., Fakih, Y. R. C., Narvaez, K. A. R., Gouvea, M. C., Espínola, C., Ferreira, C. F., de Castro, W. A. C., Pamplona, F. A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251389608 · Cited by 25
Coelho, A. A., Bastos, S., Gobira, P. H., & Lisboa, S. F. D. S. (2023) · Neuronal Signaling · doi:10.1042/ns20220034 · Cited by 24
MAP kinase cascades regulating axon regeneration in C. elegans
Pastuhov, S. I., Hisamoto, N., & Matsumoto, K. (2015) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.91.63 · Cited by 24
Potential of Endocannabinoids to Control Bladder Pain
Bjorling, D. E., & Wang, Z.-Y. (2018) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2018.00017 · Cited by 24
“N-arachidonoyl ethanolamine (anandamide or AEA) and 2-arachidonoylglycerol (2-AG) are the most widely recognized and best characterized endocannabinoids, and 2-AG is the most abundant endocannabinoid identified to date (Palmer et al., 2002; Di Marzo et al., 2004; Kogan and Mechoulam, 2006).”
BackgroundWyrofsky, R. R., Reyes, B. A. S., Yu, D., Kirby, L. G., & Bockstaele, E. J. V. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14103 · Cited by 24
Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use
George, N., Gean, E. G., Nandi, A., Фролов, Б. А., Zaidi, E., Lee, H., Brašić, J. R., & Wong, D. F. (2015) · CNS Drugs · doi:10.1007/s40263-015-0237-z · Cited by 24
“The endogenous cannabinoid system helps modulate multiple physiologic processes in the human body [28] and plays an important role in regulation of food intake, motor function, energy homeostasis, reward, attention, and memory processes in the brain [29–31].”
BackgroundMechanisms of HIV-1 Inhibition by the Lipid Mediator N-Arachidonoyldopamine
Sancho, R., de la Vega, L., Macho, A., Appendino, G., Marzo, V. D., & Muñóz, E. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3990 · Cited by 24
“In this sense, experimental evidence indicates that endocannabinoids may protect neurons from toxic insults such as glutaminergic overstimulation, ischemia, excess of NO generation, and oxidative stress through a CB1 receptor pathway (2, 65).”
BackgroundInfluentialSelf-citationNaderi, N., Majidi, M., Mousavi, Z., Tusi, S. K., Mansouri, Z., & Khodagholi, F. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0672-2 · Cited by 24
“[2] reported that GPR55 is a cannabinoid receptor, based on their data that D9-THC, anandamide and JWH-015 increased intracellular calcium in large dorsal root ganglion neurons [3].”
Veiga, M. A. L., Bloise, F. F., Costa-e-Sousa, R. H., Souza, L. L., Almeida, N. A. D. S., Oliveira, K. J., & Pazos-Moura, C. C. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0380 · Cited by 24
“This system participates in several physiological processes, such as nociceptive transmission, motor activity, learning and memory process, emotional responses, as well as thermoregulation and appetite regulation (Di Marzo et al. 2004, Foster-Schubert & Cummings 2006).”
BackgroundInfluentialLarsson, J. E., Karlsson, U., Wu, X., & Liin, S. I. (2020) · The Journal of General Physiology · doi:10.1085/jgp.202012576 · Cited by 24
Janero, D. R., & Makriyannis, A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0047-1 · Cited by 24
“Δ 9 -THC and synthetic CB-receptor activators, including levonantradol and WIN55212-2, have been studied clinically for alleviation of emesis; motor-related symptoms in patients with multiple sclerosis, Tourette’s syndrome, or Parkinson’s disease; intraocular pressure in glaucoma patients; neuropathic pain; or post-tr…”
BackgroundInfluentialCaro, J. J., Stillman, I. Ö., Danel, A., Getsios, D., & McEwan, P. (2007) · Journal of Medical Economics · doi:10.3111/13696990701438629 · Cited by 24
Kushner, R. F. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1339 · Cited by 24
“The brain ECS is thought to control food intake through reinforcing motivation to find and consume foods with high incentive value and regulating the actions of other mediators of appetite [32] .”
BackgroundCannabis constituents modulate ∆9-tetrahydrocannabinol-induced hyperphagia in rats
Farrimond, J. A., Hill, A. J., Whalley, B. J., & Williams, C. M. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1821-z · Cited by 24
“A common in vivo effect of cannabis is an increase in appetite (Di Marzo et al. 2004).”
BackgroundWasik, A. M., Christensson, B., & Sander, B. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.004 · Cited by 23
“Numerous animal studies using cannabinoids in behavioural studies, to treat inflammatory conditions and to inhibit tumour growth, angiogenesis and metastasis have been undertaken [43,75,80].”
BackgroundDrolet, B., Simard, C., & Poirier, P. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707040-00005 · Cited by 23
The endocannabinoid system in zebrafish and its potential to study the effects of Cannabis in humans
Bailone, R. L., Fukushima, H. C. S., de Aguiar, L. K., & Borra, R. C. (2022) · Laboratory Animal Research · doi:10.1186/s42826-022-00116-5 · Cited by 23
“Evidently, because of their large quantity in the central nervous system (CNS), neurotransmitters are the main candidates for their interaction [46, 50].”
BackgroundBiphasic effects of anandamide on behavioural responses: emphasis on copulatory behaviour
Rodríguez–Manzo, G., & Canseco-Alba, A. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000154 · Cited by 23
“…endogenous ligands for these receptors (eCN) and the enzymatic systems involved in their biosynthesis and degradation (Freund et al., 2003; Di Marzo et al., 2004; Fride, 2005; Mechoulam and Parker, 2013). eCN are endogenous lipid transmitters derived from arachidonic acid that are…”
BackgroundReview: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications
Sookoian, S. C., & Pirola, C. J. (2007) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944707082702 · Cited by 23
3‐Heterocycle‐Phenyl N‐Alkylcarbamates as FAAH Inhibitors: Design, Synthesis and 3D‐QSAR Studies
Käsnänen, H., Myllymäki, M. J., Minkkilä, A., Kataja, A. O., Saario, S. M., Nevalainen, T., Koskinen, A. M. P., & Poso, A. (2009) · ChemMedChem · doi:10.1002/cmdc.200900390 · Cited by 23
Endocannabinoids as endometrial inflammatory markers in lactating Holstein cows
Bonsale, R., Sharifi, R. S., Dirandeh, E., Hedayat, N., Mojtahedin, A., Ghorbanalinia, M., & Abolghasemi, A. (2018) · Reproduction in Domestic Animals · doi:10.1111/rda.13169 · Cited by 23
The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia
Gerdeman, G. L., & Fernández‐Ruíz, J. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_21 · Cited by 23
Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity
Duffy, D., & Rader, D. J. (2007) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2006.11.003 · Cited by 23
CB1 Cannabinoid Receptor Antagonists
Barth, F. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40007-x · Cited by 23
El problema del consumo de cannabis: el papel del Sector Salud
del Bosque, J., Fernández, C., Huesca, R. S., Díaz, D. B., Gutiérrez-López, A. D., Mairena, A. F., Espínola-Nadurille, M., González, N., Abdalá, A. L., Medina-Mora, M. E., et al. (2013) · Salud Mental · doi:10.17711/sm.0185-3325.2013.018 · Cited by 23
“Allergol Immunopathol (Madr) 2011;39(5):271-279.”
Dziemitko, S., Harasim‐Symbor, E., & Chabowski, A. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221143239 · Cited by 22
Siegmund, S., Wojtalla, A., Schlosser, M., Zimmer, A., & Singer, M. V. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.033 · Cited by 22
“food intake, emotions, pain perception, or sleep [11–13].”
BackgroundVerdurand, M., Dalton, V. S., & Zavitsanou, K. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.032 · Cited by 22
Wyrofsky, R. R., Reyes, B. A. S., & Bockstaele, E. J. V. (2017) · Brain Structure and Function · doi:10.1007/s00429-017-1381-7 · Cited by 22
“Keywords Norepinephrine · Psychiatric disorders · Arousal · Addiction”
Li, Y., Krogh, K. A., & Thayer, S. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.014 · Cited by 22
“The eCB system regulates processes ranging from appetite and emesis to mood and memory (Di Marzo et al., 2004).”
BackgroundLocalization of an endocannabinoid system in the hypophysial pars tuberalis and pars distalis of man
Yasuo, S., Unfried, C., Kettner, M., Geißlinger, G., & Korf, H. (2010) · Cell and Tissue Research · doi:10.1007/s00441-010-1066-5 · Cited by 22
“They are involved in many biological functions such as food intake, thermoregulation, nociceptive processing, synaptic plasticity, and immunomodulation (Di Marzo et al. 2004; Piomelli 2003; Kunos 2007).”
BackgroundHypoadiponectinemia as a Marker of Adipocyte Dysfunction—Part I: The Biology of Adiponectin
Stern, N., Osher, E., & Greenman, Y. (2007) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2007.06597.x · Cited by 22
Lingegowda, H., Miller, J. E., Marks, R. M., Symons, L. K., Alward, T. A., Lomax, A. E., Koti, M., & Tayade, C. (2021) · Frontiers in Reproductive Health · doi:10.3389/frph.2021.726936 · Cited by 21
Klatzkow, S., Davis, G., Shmalberg, J. W., Gallastegui, A., Miscioscia, E., Tarricone, J., Elam, L., Johnson, M. D., Leonard, K. M., & Wakshlag, J. J. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.1036056 · Cited by 21
Zhang, T., Xie, L., Guo, Y., Wang, Z., Guo, X., Liu, R., Jin, Q., Chang, M., & Wang, X. (2024) · Research · doi:10.34133/research.0377 · Cited by 21
“The ECS is a crucial lipid signaling system comprising 2 G protein-coupled receptors, lipid ligands, and enzymes responsible for ligand synthesis [14].”
BackgroundThe endocannabinoid system as a therapeutic target in neuropathic pain: a review
Quintero, J.-M., Díaz, L. E., Galve‐Roperh, I., Bustos, R., Leon, M.-X., Beltran, S., & Dodd, S. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2407824 · Cited by 21
“This system comprises three key components: endocannabinoids, receptors, and enzymes [44].”
Pharmacotherapies for Overeating and Obesity
Yarnell, S. C. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000131 · Cited by 21
“Nevertheless, there are other cannabinoid drugs currently under investigation including: dronabinol, nabilone, sativex, levonantradol, WIN55212-2, AM 251, AM4113, SR141716A, V24343, SR-147778, SLV319, MK-0364, and CP-945,598 [102,163-166].”
No more pain upon G q‐protein‐coupled receptor activation: role of endocannabinoids
Hu, S. S., Ho, Y., & Chiou, L. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12475 · Cited by 21
“Several putative anandamide transporter inhibitors, such as AM404, VDM11, and LY218240, have been shown to enhance the effects of anandamide (Beltramo et al., 1997; Di Marzo et al., 2004).”
BackgroundRetractedBorges, R. S., & da Silva, A. B. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00093-4 · Cited by 21
Reynoso-Moreno, I., Chicca, A., Flores-Soto, M. E., Paredes, J. M. V., & Gertsch, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00180 · Cited by 21
“The indirect modulation of EC levels is an attractive therapeutic strategy as it may lead to fewer adverse effects than the direct activation of CB1 receptors in terms of neurotransmission, metabolism and immunomodulation (Di Marzo et al., 2004).”
BackgroundThe endocannabinoid system: Novel targets for treating cancer induced bone pain
Sun, J., Zhou, Y., Chen, S., Wang, X., Xu, B., Li, D., Tian, Y., & Ye, D. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109504 · Cited by 21
Lüdtke, D. D., Siteneski, A., Galassi, T. D. O., Buffon, A. C., Cidral‐Filho, F. J., Reed, W. R., Salgado, A. S. I., Santos, A. R. S., & Martins, D. F. (2020) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.13705 · Cited by 21
Huang, G., Pemp, D., Stadtmüller, P., Nimczick, M., Heilmann, J., & Decker, M. W. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.07.038 · Cited by 21
Bouron, A. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.04.003 · Cited by 21
The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain
Maione, S., Starowicz, K., Palazzo, E., Rossi, F., & Marzo, V. D. (2006) · Drug Development Research · doi:10.1002/ddr.20098 · Cited by 21
Self-citationScheen, A. J., Gaal, L. G. V., Després, J., Pi-Sunyer, X., Golay, A., & Hanotin, C. (2006) · PubMed · Cited by 21
Laere, K. V. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0505-3 · Cited by 21
“The ECS plays an important role in metabolism and immunological reactions [10] and is critically involved in motor functions and reward processing [11].”
BackgroundPreclinical science regarding cannabinoids as analgesics: An overview
Lynch, M. (2005) · Pain Research and Management · doi:10.1155/2005/169093 · Cited by 20
Quais são e pra que servem os medicamentos à base de Cannabis?
Pamplona, F. A. (2014) · Revista da Biologia · doi:10.7594/revbio.13.01.05 · Cited by 20
“…inibidores da recaptação e/ ou degradação que aumentam os níveis endógenos dos canabinoides, moduladores alostéricos que fazem uma regulagem fina dos receptores, e extratos padronizados contendo fitocanabinoides (Baker et al., 2003, Di Marzo et al., 2004, Pamplona and Takahashi, 2012).”
BackgroundTherapeutic Potential of Palmitoylethanolamide in Gastrointestinal Disorders
Branković, M., Gmizić, T., Dukić, M., Zdravkovic, M. D., Daskalovic, B., Mrda, D., Nikolić, N., Brajković, M., Gojgić, M., Lalatović, J., et al. (2024) · Antioxidants · doi:10.3390/antiox13050600 · Cited by 20
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.